Crystal form of pyrimido azacyclo compound, and preparation method therefor and use thereof

By developing specific crystal forms of pyrimidine-oxazaxin heterocyclic compounds, the targeting and stability of existing RET kinase inhibitors have been solved, bioavailability and efficacy have been improved, and it is suitable for the treatment of RET gene-related cancers.

WO2024234384A1PCT designated stage expired Publication Date: 2024-11-21TYK MEDICINES INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/095142
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-18
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing RET kinase inhibitors have low targeting and serious toxicity problems in the treatment of RET gene-related cancers, and the instability of the compounds makes it difficult to control the quality of the drug, affecting bioavailability and efficacy.

Method used

A crystal form of pyrimidine-azacyclic compounds, including free alkali crystal form III, fumarate crystal form I and malate crystal form I, was developed, and was identified by X-ray powder diffraction pattern, DSC and TGA. Its stability and structure improve the solubility and bioavailability of compounds.

Benefits of technology

It has achieved improvements in the physical stability and bioavailability of compounds, reduced toxicity risks, ensured the quality stability and efficacy of drugs, and was suitable for the treatment of RET-regulated diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023095142_21112024_PF_FP_ABST
    Figure CN2023095142_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a crystal form of a pyrimido azacyclo compound, and a preparation method therefor and a use thereof. Particularly, disclosed in the present invention are a series of crystal forms of a compound of formula A, wherein the crystal forms have excellent stability. Further disclosed in the present invention are a preparation method for the crystal forms and a use of the crystal forms in the prevention and / or treatment of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

A crystal form of a pyrimido-azaheterocyclic compound, its preparation method and application Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a crystal form of a pyrimido-azaheterocyclic compound, a preparation method and an application thereof. Background Art

[0002] The RET (Rearranged during transfection) gene, located on chromosome 10, encodes the RET protein, a receptor tyrosine kinase (RTK) present on the cell membrane. Mutations in RET include fusions with genes such as KIF5B, TRIM33, CCDC6, and NCOA4, as well as point mutations at sites such as M918T. Common RET mutations occur in various cancer types, including thyroid cancer and non-small cell lung cancer. RET gene fusions occur in approximately 1% to 2% of patients with NSCLC and 10% to 20% of patients with papillary thyroid carcinoma (which accounts for approximately 85% of all thyroid cancers). RET fusions are more common in younger patients, particularly young, non-smoking patients with lung adenocarcinoma, with an incidence as high as 7% to 17%. Current treatment options for RET gene alterations primarily use multikinase inhibitors, such as cabozantinib and vandetanib. However, due to their limited targeting, these drugs often result in severe toxicities related to off-target VEGFR inhibition.

[0003] Blueprint Pharmaceuticals and Loxo Oncology announced the development of BLU-667 and LOXO-292, two highly potent and selective oral RET inhibitors. Blueprint's clinical data showed that BLU-667 exhibited broad anti-tumor activity, with an overall response rate (ORR) of 45% in patients with tumors harboring RET fusions and mutations, including 50% in non-small cell lung cancer (NSCLC) and 40% in medullary thyroid cancer (MTC). The U.S. FDA granted Breakthrough Therapy designation to Loxo Oncology's investigational drug, LOXO-292, for the treatment of patients with RET gene mutations in non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC).

[0004] Therefore, the development of new compounds with RET kinase inhibitory activity and better pharmacodynamics and pharmacokinetic properties has become an important research project for the development of new anti-tumor drugs, and will ultimately be used in the treatment of human tumors and other diseases.

[0005] The Chinese patent application publication number CN113698390A discloses a series of compounds used as RET kinase inhibitors. The series of compounds disclosed in this patent have very good RET inhibitory activity. A compound with a structural formula as shown in formula (A) is disclosed in this patent application. There are currently no reports on patents regarding the crystal form of this compound. Screening and developing crystal forms of the compound represented by formula (A) to find stable and reliable crystal forms to ensure the quality stability of the compound represented by formula (A) so that it can be better used in pharmacy and drug preparations and future clinical use, to achieve stable and controllable drug quality, as well as better dissolution and higher bioavailability, thereby avoiding safety issues such as side effects caused by toxic impurities produced by unstable drugs, will be of great significance for later advancement.

[0006] Summary of the Invention

[0007] The purpose of the present invention is to provide a crystal form of a pyrimido-azaheterocyclic compound, a preparation method and an application thereof.

[0008] In a first aspect of the present invention, a crystalline form of a compound of formula A is provided, wherein the crystalline form is selected from the group consisting of free base crystalline form III, fumarate crystalline form I, and malate crystalline form I.

[0009] in,

[0010] The X-ray powder diffraction pattern of the free base crystalline form III has characteristic peaks at the following 2θ values: 5.1±0.2°, 5.8±0.2°, 7.3±0.2°, 8.2±0.2°, 9.3±0.2°, 10.4±0.2°, 10.7±0.2°, 13.0±0.2°, 13.3±0.2°, 14.7±0.2°, 16.7±0.2°, 18.4±0.2°, 19.0±0.2°, and 23.4±0.2°;

[0011] The X-ray powder diffraction pattern of the fumarate salt form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 8.7±0.2°, 10.6±0.2°, 14.6±0.2°, 15.5±0.2°, 17.5±0.2°, 18.0±0.2°, 19.2±0.2°, and 27.1±0.2°;

[0012] The X-ray powder diffraction pattern of the malate salt form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 9.3±0.2°, 10.7±0.2°, 11.2±0.2°, 11.8±0.2°, 15.3±0.2°, 17.3±0.2°, 17.6±0.2°, 18.3±0.2°, 19.0±0.2°, 23.5±0.2°, 25.7±0.2°, and 28.0±0.2°.

[0013] In another preferred embodiment,

[0014] The X-ray powder diffraction pattern of the free base crystalline form III has characteristic peaks at the following 2θ values: 5.1±0.2°, 5.8±0.2°, 7.3±0.2°, 7.8±0.2°, 8.2±0.2°, 9.3±0.2°, 10.4±0.2°, 10.7±0.2°, 11.0±0.2°, 13.0±0.2°, 13.3±0.2°, 14.0±0.2°, 14.7±0.2°, 15.2±0.2°, 16.7±0.2°, 17.5±0.2°, 18.4±0.2°, 19.0±0.2°, 21.1±0.2°, 22.2±0.2°, 23.4±0.2°, and 29.5±0.2°;

[0015] The X-ray powder diffraction pattern of the fumarate salt form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 8.7±0.2°, 10.6±0.2°, 11.0±0.2°, 11.9±0.2°, 12.1±0.2°, 12.5±0.2°, 14.6±0.2°, 15.5±0.2°, 15.9±0.2°, 17.5±0.2°, 18.0±0.2°, 19.2±0.2°, 26.7±0.2°, and 27.1±0.2°;

[0016] The X-ray powder diffraction pattern of the malate salt form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 9.3±0.2°, 10.2±0.2°, 10.7±0.2°, 11.2±0.2°, 11.8±0.2°, 13.2±0.2°, 15.3±0.2°, 16.2±0.2°, 17.3±0.2°, 17.6±0.2°, 18.3±0.2°, 19.0±0.2°, 23.5±0.2°, 24.8±0.2°, 25.7±0.2°, 27.6±0.2°, and 28.0±0.2°.

[0017] In another preferred embodiment,

[0018] The X-ray powder diffraction pattern of the free base crystalline form III has characteristic peaks at the following 2θ values: 5.1±0.2°, 5.8±0.2°, 7.3±0.2°, 7.8±0.2°, 8.2±0.2°, 9.3±0.2°, 10.4±0.2°, 10.7±0.2°, 11.0±0.2°, 13.0±0.2°, 13.3±0.2°, 14.0±0.2°, 14.7±0.2°, 15.2±0 .2°, 16.7±0.2°, 17.5±0.2°, 18.4±0.2°, 19.0±0.2°, 21.1±0.2°, 21.6±0.2°, 22.2±0.2°, 23.4±0.2°, 24.9±0.2°, 25.9±0.2°, 26.3±0.2°, 27.9±0.2°, 28.4±0.2°, 29.5±0.2°, 30.0±0.2°, 35.6±0.2°;

[0019] The X-ray powder diffraction pattern of the fumarate salt form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 8.2±0.2°, 8.7±0.2°, 9.9±0.2°, 10.6±0.2°, 11.0±0.2°, 11.9±0.2°, 12.1±0.2°, 12.5±0.2°, 14.6±0.2°, 1 5.5±0.2°, 15.9±0.2°, 16.5±0.2°, 17.5±0.2°, 18.0±0.2°, 19.2±0.2°, 21.2±0.2°, 22.2±0.2°, 23.9±0.2°, 25.5±0.2°, 26.7±0.2°, 27.1±0.2°, 28.8±0.2°;

[0020] The X-ray powder diffraction pattern of the malate salt form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 9.3±0.2°, 10.2±0.2°, 10.7±0.2°, 11.2±0.2°, 11.8±0.2°, 12.1±0.2°, 13.2±0.2°, 15.3±0.2°, 16.2±0.2°, 16.8±0.2°, 17.1±0.2°, 17.3±0.2°, 17.6±0.2°, 18.3±0.2°, 19.0±0.2°, 23.5±0.2°, 24.8±0.2°, 25.2±0.2°, 25.7±0.2°, 27.6±0.2°, 28.0±0.2°, 29.7±0.2°.

[0021] In another preferred embodiment,

[0022] The X-ray powder diffraction pattern of the free base Form III is substantially as shown in FIG5 ;

[0023] The X-ray powder diffraction pattern of the fumarate salt form I is substantially as shown in FIG37 ;

[0024] The X-ray powder diffraction pattern of the malate salt form I is basically shown in Figure 41.

[0025] In another preferred embodiment, the crystal form is selected from the following group: fumarate crystal form I, malate crystal form I.

[0026] In another preferred embodiment, the crystal form is fumarate crystal form I.

[0027] In another preferred embodiment, the fumarate salt crystal form I is triclinic, P1 space group.

[0028] In another preferred embodiment, in the fumarate salt crystal form I, each asymmetric unit contains two free base molecules and one fumaric acid molecule, and each unit cell contains one asymmetric unit.

[0029] In another preferred embodiment, the unit cell parameter of the fumarate salt crystal form I is a=9.7377(2), α=105.363°, β=91.357°, γ=109.397°, Z=1.

[0030] The second aspect of the present invention provides a method for preparing the free base crystalline form III, which is selected from the group consisting of:

[0031] Method 1: Mix the compound represented by formula A with solvent m, dissolve it, and crystallize it; the solvent m is selected from one of n-butanone, acetone and acetonitrile;

[0032] Method 2: The compound represented by formula A is mixed with a solvent n, beaten at high temperature, and crystallized; the solvent n is selected from one of ethyl acetate, isopropyl acetate and methyl tert-butyl ether.

[0033] In another preferred embodiment, the compound represented by formula A is free base crystal form I.

[0034] In another preferred embodiment, the "high temperature" is 50-70°C.

[0035] The third aspect of the present invention provides a method for preparing the fumarate crystalline form I or the malate crystalline form I, wherein the method is selected from the group consisting of:

[0036] Method 1: dissolving the compound of formula A in an organic solvent, stirring at room temperature, then adding fumaric acid or malic acid, continuing stirring, and performing solid-liquid separation to obtain the fumarate salt form I or malate salt form I;

[0037] Method 2: adding an organic solvent to the fumarate or malate of the compound of formula A, suspending and stirring, and performing solid-liquid separation to obtain the fumarate crystal form I or malate crystal form I.

[0038] In another preferred embodiment, the organic solvent is 2-methyltetrahydrofuran.

[0039] The fourth aspect of the present invention provides a use of the crystal form described in the first aspect of the present invention for preparing a drug, wherein the drug is used for a use selected from the group consisting of:

[0040] 1) Treating diseases or conditions associated with RET regulation;

[0041] 2) Treat tumors;

[0042] 3) Inhibit cell proliferation.

[0043] In another preferred embodiment, the disease or condition related to RET regulation is selected from the following group: thyroid cancer, non-small cell lung cancer.

[0044] In another preferred embodiment, the cells are selected from the group consisting of human thyroid cancer cells and human lung cancer cells.

[0045] In another preferred embodiment, the tumor is selected from the following group: thyroid cancer and non-small cell lung cancer.

[0046] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] FIG1 is an X-ray powder diffraction pattern of the free base crystalline form I of the present invention;

[0048] FIG2 is a DSC-TGA spectrum of the free base crystalline form I of the present invention;

[0049] FIG3 is an X-ray powder diffraction pattern of the free base crystalline form II of the present invention;

[0050] FIG4 is a DSC-TGA spectrum of the free base crystal form II of the present invention;

[0051] FIG5 is an X-ray powder diffraction pattern of the free base crystalline form III of the present invention;

[0052] FIG6 is a DSC-TGA spectrum of the free base form III of the present invention;

[0053] FIG7 is an X-ray powder diffraction pattern of the free base crystalline form IV of the present invention;

[0054] FIG8 is a DSC-TGA spectrum of the free base form IV of the present invention;

[0055] FIG9 is an X-ray powder diffraction pattern of the free base crystalline form V of the present invention;

[0056] FIG10 is a DSC-TGA spectrum of the free base crystalline form V of the present invention;

[0057] FIG11 is an X-ray powder diffraction pattern of the free base crystalline form VI of the present invention;

[0058] FIG12 is a DSC-TGA spectrum of the free base Form VI of the present invention;

[0059] FIG13 is an X-ray powder diffraction pattern of the free base Form VII of the present invention;

[0060] FIG14 is a DSC-TGA spectrum of the free base Form VII of the present invention;

[0061] FIG15 is an X-ray powder diffraction pattern of the free base Form VIII of the present invention;

[0062] FIG16 is a DSC-TGA spectrum of the free base Form VIII of the present invention;

[0063] FIG17 is an X-ray powder diffraction pattern of the free base Form IX of the present invention;

[0064] FIG18 is a DSC-TGA spectrum of the free base Form IX of the present invention;

[0065] FIG19 is an X-ray powder diffraction pattern of the hydrochloride salt form I of the present invention;

[0066] FIG20 is a DSC-TGA spectrum of the hydrochloride salt Form I of the present invention;

[0067] FIG21 is an X-ray powder diffraction pattern of the p-toluenesulfonate crystalline form I of the present invention;

[0068] FIG22 is a DSC-TGA spectrum of the p-toluenesulfonate crystalline form I of the present invention;

[0069] FIG23 is an X-ray powder diffraction pattern of the mesylate salt Form I of the present invention;

[0070] FIG24 is a DSC-TGA spectrum of the mesylate salt Form I of the present invention;

[0071] FIG25 is an X-ray powder diffraction pattern of Form I of the benzenesulfonate salt of the present invention;

[0072] FIG26 is a DSC-TGA spectrum of benzenesulfonate salt Form I of the present invention;

[0073] FIG27 is an X-ray powder diffraction pattern of the oxalate salt form I of the present invention;

[0074] FIG28 is a DSC-TGA spectrum of the oxalate salt form I of the present invention;

[0075] FIG29 is an X-ray powder diffraction pattern of the oxalate salt form II of the present invention;

[0076] FIG30 is a DSC-TGA spectrum of the oxalate salt form II of the present invention;

[0077] FIG31 is an X-ray powder diffraction pattern of maleate salt Form I of the present invention;

[0078] FIG32 is a DSC-TGA spectrum of maleate salt Form I of the present invention;

[0079] FIG33 is an X-ray powder diffraction pattern of the phosphate crystal form I of the present invention;

[0080] FIG34 is a DSC-TGA spectrum of the phosphate crystal form I of the present invention;

[0081] FIG35 is an X-ray powder diffraction pattern of the tartrate salt Form I of the present invention;

[0082] FIG36 is a DSC-TGA spectrum of the tartrate salt Form I of the present invention;

[0083] FIG37 is an X-ray powder diffraction pattern of the fumarate salt Form I of the present invention;

[0084] FIG38 is a DSC-TGA spectrum of the fumarate salt Form I of the present invention;

[0085] FIG39 is an X-ray powder diffraction pattern of the citrate salt Form I of the present invention;

[0086] FIG40 is a DSC-TGA spectrum of the citrate salt Form I of the present invention;

[0087] FIG41 is an X-ray powder diffraction pattern of the malate salt Form I of the present invention;

[0088] FIG42 is a DSC-TGA spectrum of the malate crystalline form I of the present invention.

[0089] Figure 43 is a single crystal structure diagram of the fumarate salt form I of the present invention (containing two free base molecules and one fumaric acid molecule, each unit cell contains one asymmetric unit, and the absolute configuration of carbon (C-8 / C-36) is S configuration).

[0090] Figure 44 is an X-ray powder diffraction pattern of the amorphous free base of the present invention.

[0091] Figures 45 and 46 are PLM images of the free base Form I of the present invention. DETAILED DESCRIPTION

[0092] After long and in-depth research, the inventors unexpectedly prepared a series of crystalline forms of the compound represented by Formula A with excellent stability, especially the free base crystalline form III, the fumarate crystalline form I, and the malate crystalline form I. On this basis, the inventors completed the present invention.

[0093] Crystal form

[0094] A drug's crystal form is the solid state in which it exists. Research on drug crystal forms is the study of the drug's fundamental state. Only with a comprehensive understanding of the crystal forms of chemical drugs can we identify the most suitable crystal forms for treating diseases. A drug's crystal form can influence its physical and chemical properties, directly impacting its clinical therapeutic efficacy. Different crystal forms of the same drug can significantly differ in appearance, solubility, melting point, dissolution rate, and bioavailability, thus affecting the drug's stability, bioavailability, and efficacy. Therefore, studying the stable crystal forms of a compound is of great significance.

[0095] The active ingredient of the same drug generally exists in two or more crystal forms, which are called drug polymorphs. Different crystal forms have different solubilities and dissolution rates, which affect the drug's clinical therapeutic effects by causing changes in in vivo bioavailability. Differences in drug crystal forms may affect its dissolution and absorption in the body, thereby affecting the drug's bioavailability, clinical efficacy and safety. At the same time, the stability of the drug crystal form is also very important. In order to improve the bioavailability of the drug, reduce toxicity, and enhance the therapeutic effect, more attention should be paid to the stability of the drug crystal form. Crystal forms with good stability can ensure the physicochemical stability of the drug dosage form during preparation and storage, maintain good solubility and bioavailability of the drug dosage form, and ensure equivalence between each batch of drugs. The same drug often has multiple crystal forms. Currently, the crystal form with better therapeutic effect and the most clinically applicable is called the dominant drug crystal form.

[0096] The present invention screened the crystal forms of the compound represented by formula (A) to identify as many different crystal forms of the active pharmaceutical ingredient as possible. The screened crystal forms were identified using methods such as powder X-ray diffraction analysis (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), hydrogen spectroscopy liquid magnetic resonance (1H NMR), and high-performance liquid chromatography (HPLC). Further thermodynamic stability and hygroscopicity studies revealed the dominant free base crystal form III, fumarate crystal form I, and malate crystal form I, providing a reference for crystal form selection in subsequent pharmacokinetic and zoological experiments.

[0097] Further pharmacokinetic studies have shown that the free base crystalline Form III, fumarate crystalline Form I, and malate crystalline Form I of Formula (A) provided herein are easily absorbed and stable in vivo, exhibiting a well-defined blood concentration distribution and high bioavailability. Furthermore, their excellent physical stability facilitates quality control during subsequent formulation development and extends shelf life, thereby achieving improved therapeutic efficacy.

[0098] In another preferred embodiment, the compound of formula A further has a crystalline form selected from the group consisting of free base crystalline form I, free base crystalline form II, free base crystalline form IV, free base crystalline form V, free base crystalline form VI, free base crystalline form VII, free base crystalline form VIII, free base crystalline form IX,

[0099] The X-ray powder diffraction pattern of the free base crystalline form I has characteristic peaks at the following 2θ values: 6.8±0.2°, 8.6±0.2°, 9.9±0.2°, 12.9±0.2°, 13.7±0.2°, and 18.8±0.2°;

[0100] The X-ray powder diffraction pattern of the free base crystalline form II has characteristic peaks at the following 2θ values: 5.4±0.2°, 8.1±0.2°, 9.7±0.2°, 10.0±0.2°, 10.5±0.2°, and 13.6±0.2°;

[0101] The X-ray powder diffraction pattern of the free base crystalline form IV has characteristic peaks at the following 2θ values: 5.7±0.2°, 8.3±0.2°, 9.5±0.2°, 11.8±0.2°, 12.2±0.2°, 12.5±0.2°, 12.9±0.2°, 13.4±0.2°, 14.4±0.2°, 15.4±0.2°, 17.3±0.2°, 18.4±0.2°, 18.6±0.2°, and 20.2±0.2°;

[0102] The X-ray powder diffraction pattern of the free base crystalline form V has characteristic peaks at the following 2θ values: 5.4±0.2°, 9.5±0.2°, 9.8±0.2°, 11.9±0.2°, and 13.7±0.2°;

[0103] The X-ray powder diffraction pattern of the free base crystalline form VI has characteristic peaks at the following 2θ values: 5.7±0.2°, 7.4±0.2°, 8.4±0.2°, 9.7±0.2°, 10.3±0.2°, 11.5±0.2°, 12.4±0.2°, 14.6±0.2°, 15.7±0.2°, 17.1±0.2°, 17.4±0.2°, 18.7±0.2°, 20.3±0.2°, and 23.1±0.2°;

[0104] The X-ray powder diffraction pattern of the free base crystalline form VII has characteristic peaks at the following 2θ values: 5.1±0.2°, 5.6±0.2°, 7.0±0.2°, 7.4±0.2°, 9.5±0.2°, 9.9±0.2°, 10.3±0.2°, 13.0±0.2°, 13.3±0.2°, 14.4±0.2°, 14.9±0.2°, 16.1±0.2°, 18.1±0.2°, 18.6±0.2°, 18.9±0.2°, and 20.6±0.2°;

[0105] The X-ray powder diffraction pattern of the free base crystalline form VIII has characteristic peaks at the following 2θ values: 5±0.2°, 8.3±0.2°, 8.6±0.2°, 10.1±0.2°, 11.2±0.2°, 12.4±0.2°, 12.6±0.2°, 13.1±0.2°, 13.6±0.2°, 17.7±0.2°, 18±0.2°, and 19.2±0.2°;

[0106] The X-ray powder diffraction pattern of the free base crystalline form IX has characteristic peaks at the following 2θ values: 7.9±0.2°, 11.8±0.2°, 15.9±0.2°, 16.4±0.2°, 17.3±0.2°, 20.0±0.2°, 20.2±0.2°, and 21.2±0.2°.

[0107] In another preferred embodiment, the X-ray powder diffraction pattern of the free base crystalline form I has characteristic peaks at the following 2θ values: 5.8±0.2°, 6.8±0.2°, 8.6±0.2°, 9.9±0.2°, 12.0±0.2°, 12.9±0.2°, 13.7±0.2°, 14.4±0.2°, 15.2±0.2°, 16.5±0.2°, 17.2±0.2°, 17.6±0.2°, 18.4±0.2°, 18.8±0.2°, 21.9±0.2°, 23.0±0.2°, 23.5±0.2°;

[0108] The X-ray powder diffraction pattern of the free base crystalline form II has characteristic peaks at the following 2θ values: 5.4±0.2°, 8.1±0.2°, 9.7±0.2°, 10.0±0.2°, 10.5±0.2°, 11.8±0.2°, 12.6±0.2°, 13.6±0.2°, 16.4±0.2°, 19.8±0.2°, and 23.0±0.2°;

[0109] The X-ray powder diffraction pattern of the free base crystalline form IV has characteristic peaks at the following 2θ values: 5.7±0.2°, 6.6±0.2°, 6.7±0.2°, 7.2±0.2°, 8.3±0.2°, 9.5±0.2°, 10.0±0.2°, 11.5±0.2°, 11.8±0.2°, 12.2±0.2°, 12.5±0.2°, 12.9±0.2°, 13 .1±0.2°, 13.4±0.2°, 14.4±0.2°, 14.6±0.2°, 15.4±0.2°, 16.1±0.2°, 16.6±0.2°, 17.3±0.2°, 17.5±0.2°, 18.0±0.2°, 18.4±0.2°, 18.6±0.2°, 20.2±0.2°, 22.7±0.2°, 23.0±0.2°;

[0110] The X-ray powder diffraction pattern of the free base crystalline form V has characteristic peaks at the following 2θ values: 5.4±0.2°, 8.2±0.2°, 9.5±0.2°, 9.8±0.2°, 11.1±0.2°, 11.9±0.2°, 12.8±0.2°, 13.7±0.2°, 16.4±0.2°, 19.2±0.2°, 20.9±0.2°, and 23.2±0.2°;

[0111] The X-ray powder diffraction pattern of the free base crystalline form VI has characteristic peaks at the following 2θ values: 5.7±0.2°, 6.7±0.2°, 7.4±0.2°, 8.4±0.2°, 9.7±0.2°, 10.3±0.2°, 11.5±0.2°, 12.0±0.2°, 12.4±0.2°, 13.0±0.2°, 13.6±0.2°, 14.6±0.2°, 15.7±0.2°, 16.2±0.2°, 17.1±0.2°, 17.4±0.2°, 18.7±0.2°, 20.3±0.2°, 21.4±0.2°, 22.8±0.2°, 23.1±0.2°, and 29.9±0.2°;

[0112] The X-ray powder diffraction pattern of the free base crystalline form VII has characteristic peaks at the following 2θ values: 5.1±0.2°, 5.6±0.2°, 7.0±0.2°, 7.4±0.2°, 7.8±0.2°, 8.7±0.2°, 9.5±0.2°, 9.9±0.2°, 10.3±0.2°, 11.7±0.2°, 12 .1±0.2°, 13.0±0.2°, 13.3±0.2°, 13.8±0.2°, 14.4±0.2°, 14.9±0.2°, 16.1±0.2°, 16.3±0.2°, 18.1±0.2°, 18.6±0.2°, 18.9±0.2°, 20.6±0.2°, 23.5±0.2°;

[0113] The X-ray powder diffraction pattern of the free base crystalline form VIII has characteristic peaks at the following 2θ values: 4.3±0.2°, 5±0.2°, 5.5±0.2°, 8.3±0.2°, 8.6±0.2°, 10.1±0.2°, 10.4±0.2°, 11.2±0.2°, 12.4±0.2°, 12.6±0.2°, 13.1 ±0.2°, 13.6±0.2°, 14.4±0.2°, 16.6±0.2°, 17.7±0.2°, 18±0.2°, 19.2±0.2°, 20.3±0.2°, 22±0.2°, 23.6±0.2°, 24.9±0.2°, 25.1±0.2°, 26.1±0.2°, 26.4±0.2°;

[0114] The X-ray powder diffraction pattern of the free base crystalline form IX has characteristic peaks at the following 2θ values: 7.9±0.2°, 8.4±0.2°, 11.8±0.2°, 13.8±0.2°, 15.9±0.2°, 16.4±0.2°, 17.3±0.2°, 19.0±0.2°, 19.2±0.2°, 20.0±0.2°, 20.2±0.2°, 21.2±0.2°, and 28.4±0.2°.

[0115] In another preferred embodiment, the X-ray powder diffraction pattern of the free base crystalline form I has characteristic peaks at the following 2θ values: 5.8±0.2°, 6.8±0.2°, 8.6±0.2°, 9.9±0.2°, 12.0±0.2°, 12.9±0.2°, 13.7±0.2°, 14.4±0.2°, 15.2±0.2°, 16.5±0.2°, 17.2±0.2°, 17.6±0. 2°, 18.1±0.2°, 18.4±0.2°, 18.8±0.2°, 19.5±0.2°, 20.5±0.2°, 21.6±0.2°, 21.9±0.2°, 22.3±0.2°, 23.0±0.2°, 23.5±0.2°, 25.1±0.2°, 25.7±0.2°, 26.1±0.2°, 29.6±0.2°, 29.9±0.2°;

[0116] The X-ray powder diffraction pattern of the free base crystalline form II has characteristic peaks at the following 2θ values: 5.4±0.2°, 6.6±0.2°, 8.1±0.2°, 9.1±0.2°, 9.7±0.2°, 10.0±0.2°, 10.5±0.2°, 11.4±0.2°, 11.8±0.2°, 12.6±0.2°, 1 3.6±0.2°, 14.6±0.2°, 16.4±0.2°, 16.8±0.2°, 19.2±0.2°, 19.8±0.2°, 21.1±0.2°, 21.7±0.2°, 22.0±0.2°, 23.0±0.2°, 23.8±0.2°, 25.6±0.2°, 29.4±0.2°;

[0117] The X-ray powder diffraction pattern of the free base crystalline form IV has characteristic peaks at the following 2θ values: 3.5±0.2°, 4.1±0.2°, 5.3±0.2°, 5.7±0.2°, 6.6±0.2°, 6.7±0.2°, 7.2±0.2°, 8.3±0.2°, 9.5±0.2°, 10.0±0.2°, 10.2± 0.2°, 10.7±0.2°, 11.5±0.2°, 11.8±0.2°, 12.2±0.2°, 12.5±0.2°, 12.9±0.2°, 13.1±0.2°, 13.4±0.2°, 14.4±0.2°, 14.6±0.2°, 15.4±0.2°, 15.6±0.2°, 16. 1±0.2°, 16.6±0.2°, 16.7±0.2°, 17.3±0.2°, 17.5±0.2°, 18.0±0.2°, 18.4±0.2°, 18.6±0.2°, 18.9±0.2°, 19.7±0.2°, 19.9±0.2°, 20.2±0.2°, 20.7±0.2°, 2 1.0±0.2°, 21.1±0.2°, 21.9±0.2°, 22.2±0.2°, 22.7±0.2°, 23.0±0.2°, 23.6±0.2°, 24.5±0.2°, 25.2±0.2°, 25.4±0.2°, 25.9±0.2°, 26.1±0.2°, 27.5±0.2°;

[0118] The X-ray powder diffraction pattern of the free base crystalline form V has characteristic peaks at the following 2θ values: 5.4±0.2°, 8.2±0.2°, 9.5±0.2°, 9.8±0.2°, 11.1±0.2°, 11.9±0.2°, 12.8±0.2°, 13.7±0.2°, 14.9±0.2°, 16.4±0.2°, 17.1±0.2°, 18. 8.7±0.2°, 19.2±0.2°, 20.3±0.2°, 20.9±0.2°, 22.0±0.2°, 22.4±0.2°, 23.2±0.2°, 25.3±0.2°, 25.8±0.2°, 26.4±0.2°, 26.9±0.2°, 28.1±0.2°, 29.0±0.2°, 30.1±0.2°;

[0119] The X-ray powder diffraction pattern of the free base crystalline form VI has characteristic peaks at the following 2θ values: 4.2±0.2°, 5.7±0.2°, 6.7±0.2°, 7.4±0.2°, 8.4±0.2°, 9.7±0.2°, 10.3±0.2°, 11.5±0.2°, 12.0±0.2°, 12.4±0.2°, 13.0±0.2°, 13.6±0.2°, 14.6±0.2°, 15 .7±0.2°, 16.2±0.2°, 17.1±0.2°, 17.4±0.2°, 18.7±0.2°, 20.3±0.2°, 21.0±0.2°, 21.4±0.2°, 22.8±0.2°, 23.1±0.2°, 25.8±0.2°, 26.3±0.2°, 27.2±0.2°, 28.8±0.2°, 29.2±0.2°, 29.9±0.2°;

[0120] The X-ray powder diffraction pattern of the free base crystalline form VII has characteristic peaks at the following 2θ values: 5.1±0.2°, 5.6±0.2°, 7.0±0.2°, 7.4±0.2°, 7.8±0.2°, 8.7±0.2°, 9.5±0.2°, 9.9±0.2°, 10.3±0.2°, 11.4±0.2°, 11.7±0.2°, 12.1±0.2°, 13.0±0.2°, 13.3±0.2°, 13.8±0.2°, 14 .4±0.2°, 14.9±0.2°, 15.5±0.2°, 16.1±0.2°, 16.3±0.2°, 16.9±0.2°, 18.1±0.2°, 18.6±0.2°, 18.9±0.2°, 19.7±0.2°, 20.6±0.2°, 21.2±0.2°, 21.8±0.2°, 22.5±0.2°, 23.1±0.2°, 23.5±0.2°, 24.9±0.2°, 25.4±0.2°;

[0121] The X-ray powder diffraction pattern of the free base crystalline form VIII has characteristic peaks at the following 2θ values: 4.3±0.2°, 5±0.2°, 5.5±0.2°, 6.7±0.2°, 8.3±0.2°, 8.6±0.2°, 9.7±0.2°, 10.1±0.2°, 10.4±0.2°, 11.2±0.2°, 12.4±0.2°, 12.6±0.2°, 13.1±0.2°, 13.6±0.2°, 14.4±0.2°, 15±0.2°, 15.6±0.2°, 16.6±0.2° , 17.7±0.2°, 18±0.2°, 18.6±0.2°, 19.2±0.2°, 20.3±0.2°, 21±0.2°, 21.3±0.2°, 22±0.2°, 22.6±0.2°, 23.1±0.2°, 23.6±0.2°, 24.9±0.2°, 25.1±0.2°, 25.7±0.2°, 26.1±0.2°, 26.4±0.2°, 27±0.2°, 27.5±0.2°, 28.9±0.2°, 30.3±0.2°, 31.8±0.2°;

[0122] The X-ray powder diffraction pattern of the free base crystalline form IX has characteristic peaks at the following 2θ values: 5.5±0.2°, 5.8±0.2°, 6.8±0.2°, 7.9±0.2°, 8.4±0.2°, 8.6±0.2°, 9.8±0.2°, 11.8±0.2°, 13.3±0.2°, 13.8±0.2°, 14.0±0.2°, 15 .9±0.2°, 16.4±0.2°, 17.3±0.2°, 17.6±0.2°, 19.0±0.2°, 19.2±0.2°, 20.0±0.2°, 20.2±0.2°, 20.6±0.2°, 21.2±0.2°, 24.2±0.2°, 27.8±0.2°, 28.4±0.2°, 29.4±0.2°.

[0123] In another preferred embodiment, the X-ray powder diffraction pattern of the free base crystalline form I is substantially as shown in FIG1 ;

[0124] The X-ray powder diffraction pattern of the free base crystal form II is substantially as shown in FIG3 ;

[0125] The X-ray powder diffraction pattern of the free base Form IV is substantially as shown in FIG7 ;

[0126] The X-ray powder diffraction pattern of the free base Form V is substantially as shown in FIG9 ;

[0127] The X-ray powder diffraction pattern of the free base Form VI is substantially as shown in FIG11 ;

[0128] The X-ray powder diffraction pattern of the free base Form VII is substantially as shown in FIG13 ;

[0129] The X-ray powder diffraction pattern of the free base Form VIII is substantially as shown in FIG15 ;

[0130] The X-ray powder diffraction pattern of the free base Form IX is substantially as shown in FIG17 .

[0131] Compared with the prior art, the present invention has the following main advantages:

[0132] 1) The crystal form has excellent stability and high solubility;

[0133] 2) Compared with the free base crystalline form I, the free base crystalline form III, the fumarate crystalline form I, and the malate crystalline form I of the present invention have better pharmacokinetic properties and higher in vivo exposure in animals.

[0134] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0135] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those familiar to those skilled in the art. Furthermore, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred embodiments and materials described herein are for illustrative purposes only.

[0136] The abbreviations in the present invention are shown in the following table

[0137] Chemical reagent abbreviations: 2-Me-THF 2-methyltetrahydrofuran ACN acetonitrile DCM dichloromethane DMSO dimethyl sulfoxide EA ethyl acetate EtOH ethanol Hept n-heptane IPA isopropyl alcohol IPAc isopropyl acetate MEK n-butyl ketone MeOH methanol MTBE methyl tert-butyl ether n-BuOH n-butanol THF tetrahydrofuran Tol toluene HCL hydrochloric acid H2SO4 sulfuric acid TS p-toluenesulfonic acid MS methanesulfonic acid BS benzenesulfonic acid OX oxalic acid MA maleic acid H3PO4 phosphoric acid TA L-tartaric acid FU fumaric acid CI citric acid monohydrate

[0138] Other abbreviations (in alphabetical order): DSC Differential Scanning Calorimetry DVS Dynamic Vapor Sorption HPLC High Performance Liquid Chromatography NMR Nuclear Magnetic Resonance Mass Spectrometry PLM Polarizing Microscope RT Room Temperature (20–25°C) TGA Thermogravimetric Analysis XRPD X-ray Powder Diffraction Fasting Simulated Intestinal Fluid FaSSIF Fully Simulated Intestinal Fluid FeSSIF Simulated Gastric Fluid

[0139] The technical solution of the present invention is described in detail below.

[0140] 1. Synthesis of the compound represented by formula (A)

[0141] The preparation method is the same as that of patent CN113698390A, and the synthetic route is as follows:

[0142] The specific steps are as follows:

[0143] Synthesis of compound 7

[0144] p-Methoxybenzyl alcohol (16.0 g, 116.4 mmol) and potassium tert-butoxide (24.9 g, 222.2 mmol) were dissolved in 400 mL of anhydrous dioxane. Compound 6 (20.0 g, 105.8 mmol) dissolved in 300 mL of dioxane was added dropwise to the reaction flask under ice bath. The solution was magnetically stirred for 2 h and gradually became colloidal. After completion of the reaction, water was added to quench the solution. The aqueous phase was extracted with ethyl acetate, and the organic phase was separated, washed with saturated brine, dried over anhydrous sodium sulfate, and dried under reduced pressure to obtain a crude product. The crude product was then slurried with petroleum ether for two hours, filtered, and dried in vacuo to obtain 28.8 g of compound 7, MS [M+H] 291.

[0145] 1 H NMR (400MHz, Chloroform-d) δ8.07 (s, 1H), 7.47 (d, J = 8.7Hz, 2H), 6.95 (d, J = 8.7Hz, 2H), 5.56 (s, 2H), 3.84 (s, 3H).

[0146] Synthesis of compound 8

[0147] Compound 7 (2.0 g, 6.80 mmol) was dissolved in 60 mL of anhydrous tetrahydrofuran, and ethanol (1.1 mL, 17.2 mmol) and triphenylphosphine (2.9 g, 11.0 mmol) were added sequentially. The reaction liquid was protected with nitrogen, and diisopropyl azodicarboxylate (2.8 g, 13.6 mmol) was added under ice bath. The temperature was naturally raised to room temperature and stirred for 3 h. Saturated brine was added to quench the reaction, and then extracted with ethyl acetate. The organic phase was separated, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain 1.78 g of compound 8, MS [M+H] 319.

[0148] 1 H NMR(400MHz,Chloroform-d)δ7.99(s,1H),7.45(d,J=8.8Hz,2H),6.94(d,J=8.7 Hz,2H),5.54(s,2H),4.45(q,J=7.2Hz,2H),3.83(s,3H),1.50(t,J=7.3Hz,3H).

[0149] Synthesis of compound 10

[0150] Compound 8 (1.78 g, 5.60 mmol) and compound 9 (1.82 g, 6.16 mmol) were dissolved in a mixed solvent of 60 mL of 1,4-dioxane and 12 mL of water. Palladium acetate (126 mg, 0.56 mmol), 1,1'-bis(diphenylphosphino)ferrocene (621 mg, 1.12 mmol), and potassium carbonate (1.16 g, 8.40 mmol) were added sequentially. The reaction mixture was stirred at 90°C under nitrogen protection overnight. After completion of the reaction, the mixture was cooled to room temperature, concentrated under reduced pressure, and extracted with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 1.52 g of compound 10, MS [M+H] 453.

[0151] 1 H NMR (400MHz, Chloroform-d) δ7.93 (s, 1H), 7.42 (s, 2H), 7.35-7.29 (m, 1H), 6.91 (d, J = 8.7Hz, 2H), 5.55 (s, 2H), 4.46 (q, J = 7. 3Hz,2H),3.81(d,J=2.9Hz,6H),3.33(s,3H),2.97–2.49(m,4H),2.41–2.20(m,1H),2.20–2.08(m,1H),1.50(t,J=7.2Hz,3H).

[0152] Synthesis of compound 11

[0153] Compound 10 (1.52 g, 3.36 mmol) was dissolved in a mixed solvent consisting of 15 mL of ethyl acetate and 15 mL of methanol. Wet palladium on carbon (152 mg) was then added, and the mixture was stirred overnight at room temperature under a hydrogen atmosphere. After completion of the reaction, the reaction solution was filtered through celite, washed with methanol, and the filtrate was concentrated under reduced pressure to yield 1.33 g of compound 11 (MS [M+H] 335).

[0154] 1 H NMR(400MHz,Chloroform-d)δ10.64(s,1H),8.00(s,1H),4.33(q,J=7.1Hz,2H),3.73(s,3H),3. 24(s,3H),2.71–2.60(m,1H),2.14(d,J=12.4Hz,2H),1.97–1.72(m,6H),1.44(t,J=7.2Hz,3H).

[0155] Synthesis of compound 12

[0156] Compound 11 (1.33 g, crude product) was dissolved in 30 mL of phosphorus oxychloride and stirred at 100°C for 3 h under nitrogen. After the reaction, the solvent was evaporated under reduced pressure, and then crushed ice was added. Saturated sodium bicarbonate solution was adjusted to neutral, and the mixture was extracted with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to yield 936 mg of compound 12, MS [M+H] 353.

[0157] 1 H NMR(400MHz,Chloroform-d)δ8.00(s,1H),4.46(q,J=7.3Hz,2H),3.73(s,3H),3.24(s,3 H),3.09–2.84(m,1H),2.13(d,J=11.8Hz,2H),2.00–1.72(m,6H),1.47(t,J=7.3Hz,3H).

[0158] Synthesis of compound 14

[0159] Compound 12 (936 mg, 2.66 mmol) and compound 13 (284 mg, 2.92 mmol) were dissolved in 15 mL of dimethyl sulfoxide, followed by the addition of diisopropylethylamine (686 mg, 5.32 mmol). The mixture was stirred at 100°C overnight under nitrogen. After completion of the reaction, the mixture was cooled to room temperature and diluted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to afford 728 mg of compound 14 (MS [M+H]: 414).

[0160] 1 H NMR(400MHz,Chloroform-d)δ7.78(s,1H),6.54(s,1H),4.44(q,J=6.3,5.3Hz,2H),3.80(s,3H), 3.33(s,3H),2.93–2.82(m,1H),2.36(s,J=6.5Hz,3H),2.23–1.62(m,8H),1.49(t,J=7.2Hz,3H).

[0161] Synthesis of compound int-A

[0162] Compound 14 (728 mg, 1.76 mmol) was dissolved in a mixed solvent consisting of 16 mL of methanol and 2 mL of water. Lithium hydroxide monohydrate (222 mg, 5.29 mmol) was added and stirred at 60°C overnight. After the reaction, the reaction solution was cooled to room temperature, the methanol was evaporated under reduced pressure, and the mixture was slurried in DCM. The mixture was filtered and used directly in the next step without purification to obtain 797 mg of crude int-A, MS [M+H] 400.

[0163] Synthesis of compound 2

[0164] Compound 1 (1.57 g, 10 mmol), 4-fluoro-1H-pyrazole (860 mg, 10 mmol), N,N-dimethylformamide (10 mL), and potassium carbonate (2.76 g, 20 mmol) were added to a 50 mL single-necked flask and the reaction was allowed to proceed at 100°C for 8 h. LC-MS indicated completion of the reaction. The reaction solution was poured into 200 mL of water with stirring, resulting in the precipitation of a solid. The solid was filtered, the filter cake washed with water, and dried to yield 1.08 g of compound 2. [M+1]: 207.03.

[0165] Synthesis of compound 3

[0166] To a 100 mL single-necked flask, compound 2 (870 mg, 4.2 mmol), R-tert-butylsulfenamide (560 mg, 4.63 mmol), tetraethyl titanate (1.92 g, 8.4 mmol), and dry tetrahydrofuran (10 mL) were added sequentially and the reaction was allowed to react at 75°C overnight. The mixture was cooled, diluted with water (30 mL), and filtered. The filtrate was extracted three times with ethyl acetate (20 mL). The organic phase was dried over anhydrous sodium sulfate, evaporated to dryness under reduced pressure, and purified by column chromatography to obtain 500 mg of the product.

[0167] Synthesis of compound 4

[0168] Compound 3 (100 mg, 0.32 mmol) and dry tetrahydrofuran (2 mL) were added sequentially to a 50 mL single-necked flask, and the temperature was lowered to -78 ° C. Lithium tri-sec-butylborohydride (0.7 mL, 0.7 mmol, 1.0 M) was added dropwise, and the mixture was reacted at -78 ° C for 1 h. Methanol (1 mL) was added to quench the reaction at -60 ° C, and the mixture was diluted with water (5 mL). The mixture was extracted three times with ethyl acetate (5 mL). The organic phase was dried, evaporated to dryness under reduced pressure, and 93 mg of the product was obtained by column chromatography.

[0169] 1 H NMR (400MHz, CDCl3) δ9.23(d,J=1.4Hz,1H),8.36(d,J=1.5Hz,1H),8.33(d,J=4.6Hz,1H),7.66(d ,J=4.3Hz,1H),4.77(p,J=6.6Hz,1H),3.74(d,J=5.9Hz,1H),1.67(d,J=6.8Hz,3H),1.22(s,9H).

[0170] Synthesis of compound 5

[0171] To a 50 mL single-necked flask, compound 4 (100 mg, 0.32 mmol), dichloromethane (3 mL), methanol (0.5 mL), and hydrogen chloride / dioxane (4 M, 1.5 mL) were added sequentially and the reaction was allowed to react at room temperature for 3 h. LC-MS confirmed the reaction was complete. The mixture was diluted with dichloromethane, filtered, and the filter cake was washed with ethyl acetate and dried to yield 67 mg of the product. [M+1]: 208.06.

[0172] Synthesis of formula (A)

[0173] Compound int-A (270 mg, 0.68 mmol) and compound 5 (165 mg, 0.68 mmol) were dissolved in 9 mL of N,N-dimethylformamide. Diisopropylethylamine (699 mg, 5.41 mmol) was added and stirred at room temperature for 15 minutes. HATU (386 mg, 1.02 mmol) was then added and stirred at room temperature for 1 hour. The reaction solution was diluted with ethyl acetate, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The product was separated and purified by HPLC to yield Formula (A), Ms[M+H] 589, and Formula (B), MS[M+H] 589.

[0174] NMR of formula (A): 1H NMR (400 MHz, Chloroform-d) δ 9.23 (d, J = 1.4 Hz, 1H), 8.37 (d, J = 1.4 Hz, 1H), 8.34 (d, J = 4.6 Hz, 1H), 7.78 (s, 1H), 7.66 (d, J = 4.3 Hz, 2H), 5.32 (p, J = 6.8 Hz, 1H), 4.44 (q, J = 7.2 Hz, 2H), 3.32 (s, 3H), 2.93–2.77 (m, 1H), 2.38 (s, 3H), 2.13–1.90 (m, 8H), 1.56 (d, J = 6.9 Hz, 3H), 1.48 (t, J = 7.2 Hz, 3H).

[0175] The obtained solid of formula (A) was characterized by XRPD. The results are shown in FIG1 , indicating that the obtained solid was free base crystalline form I.

[0176] The free base crystal form I was used as a raw material for the following crystal form preparation and salt form preparation experiments.

[0177] II. Preparation and Evaluation of the Crystalline Form of the Compound Represented by Formula (A)

[0178] The solubility of Form I free base was assessed visually in 17 solvents at room temperature. 5 mg of Form I free base was weighed into an 8 mL vial, and solvent was gradually added dropwise until the drug dissolved or the OD reached 1600 V. The solubility (mg / mL) was roughly calculated. The results are shown in Table 1. Form I free base exhibited high solubility (>40 mg / mL) in DMSO and THF, but poor solubility in the remaining solvents.

[0179] Table 1 Rough solubility results of free base crystal form I

[0180] If it is not dissolved, it is marked with "<", and if it is dissolved, it is marked with ">".

[0181] 1. Crystal form screening method

[0182] The solid crystal form screening of the compound of formula (A) is carried out by crystallization or precipitation from a selected single solvent or a mixed solvent thereof to obtain metastable and stable crystal forms. The methods used include evaporation crystallization, slurry crystallization, cooling crystallization, and antisolvent precipitation.

[0183] 1.1 Volatile crystallization

[0184] Based on solubility data, perform evaporative crystallization in a selected solvent. Dissolve 5 mg of Form I free base in 0.5 mL of solvent at room temperature or 50°C with stirring for 20 minutes to form a clear solution. Split the solution into two equal portions. Drain one portion with nitrogen for rapid evaporation, and cover the other portion with a perforated film for slow evaporation at room temperature.

[0185] 1.2 Beating crystallization

[0186] 30 mg of free base Form I was weighed into a sample bottle, solvent was added to form a suspension, and the suspension was stirred at RT or 50° C. for 7 days, or at 70° C. for 2 days. The solid was collected by filtration, and the filter cake was characterized by XRPD.

[0187] 1.3 Cooling crystallization

[0188] Weigh 15 mg of Form I free base into a sample vial, slowly add solvent (0.5 mL), and stir at 50°C or 40°C (DCM) for 10 minutes. Once the solution is nearly clear, microfiltration is performed to obtain the mother liquor. Divide the solution into two equal portions. Place one portion of the mother liquor in a refrigerator (~4°C) for rapid cooling. Place the other portion in a heated metal block and allow it to cool naturally to room temperature. If solid precipitates, characterize immediately.

[0189] 1.4 Antisolvent precipitation

[0190] Dissolve 15–25 mg of Form I free base in THF (0.5 mL) or DMSO (0.25 mL) at room temperature and filter to obtain a clear solution. Add antisolvent gradually, 0.1–1 mL at a time, until solid precipitates or the volume of solvent added reaches 10 V. If a precipitate forms, characterize it immediately.

[0191] 2. Crystal form analysis method

[0192] 2.1 Polarized light microscopy (PLM)

[0193] PLM analysis was performed using an ECLIPSE LV100POL (Nikon, JPN) polarizing microscope. A small amount of sample was spread onto a glass slide, cedar oil was added to disperse the sample, and a coverslip was applied. The sample was then observed under a microscope using a 4-20x objective lens.

[0194] 2.2 X-ray powder diffraction (XRPD)

[0195] Solid samples were tested using an X-ray diffractometer. The samples were spread flat on a zero-background single-crystal silicon sample plate, gently pressed flat, and analyzed according to the parameters in Table 2.

[0196] Table 2 XRPD test parameters

[0197] 2.3 Thermogravimetric analysis (TGA)

[0198] TGA data were collected using a TA instrument. 1-5 mg of sample was placed in a tareed, open aluminum sample pan. The sample was heated according to the instrument parameters listed in Table 3, and the data was analyzed and processed using TRIOS software.

[0199] Table 3. TGA test parameters

[0200] 2.4 Differential Scanning Calorimetry (DSC)

[0201] DSC data for the samples were collected using a TA instrument. 1-3 mg of sample was placed in a perforated DSC pan and heated according to the parameters in Table 4. The data were analyzed and processed using TRIOS software.

[0202] Table 4. DSC test parameters

[0203] 3. Crystal form analysis results

[0204] 3.1 Free base form I

[0205] The free base crystal form I was obtained by slurrying in MeOH, EtOH and IPA systems at room temperature and 50°C, and by anti-solvent precipitation in IPA / THF system.

[0206] The XRPD results of the free base form I are shown in Figure 1, and the DSC and TGA results are shown in Figure 2. 1H-NMR showed that the sample contained 5.4% ethanol, 0.8% n-heptane, and an unknown solvent residue. At the same time, TGA showed a 1.5% weight loss before 80°C and a 5.2% weight loss from 80°C to 200°C, which was attributed to the removal of the solvent. DSC showed multiple endothermic peaks before 250°C, which were attributed to desolvation and sample melting.

[0207] As can be seen from Figure 1, the X-ray powder diffraction peak data of the free base crystal form I are shown in Table 5.

[0208] Table 5

[0209] 3.2 Free base crystal form II

[0210] The free base crystal form I is dissolved in trifluoroacetic acid, acetonitrile and water system, and the obtained solution is adjusted to alkaline with sodium bicarbonate. After the organic solvent is concentrated under reduced pressure, the suspension is filtered and the solid is washed with water to obtain the free base crystal form II.

[0211] 1H-NMR showed that the sample contained 0.2% residual n-heptane, while TGA showed a 1.8% weight loss before 70°C and a 2.5% weight loss between 70°C and 145°C, attributed to the removal of water or solvent. The DSC curve showed multiple endothermic peaks before 200°C, attributed to desolvation and sample melting. Therefore, it is speculated that the free base Form II is a hydrated form. The X-ray powder diffraction pattern (XRPD) and DSC-TGA spectrum obtained using Cu-Kα radiation are shown in Figures 3 and 4.

[0212] As can be seen from Figure 3, the X-ray powder diffraction peak data of the free base crystal form II are shown in Table 6.

[0213] Table 6

[0214] 3.3 Free base form III

[0215] The free base crystal form III was obtained by slurrying at room temperature or high temperature of 50 / 70°C for n-butanone, acetone and acetonitrile, and at high temperature of 50 / 70°C for ethyl acetate, isopropyl acetate and methyl tert-butyl ether.

[0216] The free base crystal form III is agglomerated microcrystals with high crystallinity. The XRPD results of the free base crystal form III are shown in Figure 5, and the DSC and TGA results are shown in Figure 6. TGA shows no obvious weight loss before 150°C. 1H-NMR shows that the sample contains 0.03% acetone residue. There is a small endothermic peak at 84°C on the DSC curve (the crystal form does not change when heated to 100°C). There is another endothermic peak at 245°C, which is the melting point of the compound. Therefore, the free base crystal form III is an anhydrous crystal form.

[0217] As can be seen from Figure 5, the X-ray powder diffraction peak data of the free base crystal form III are shown in Table 7.

[0218] Table 7

[0219] 3.4 Free base form IV

[0220] Form IV was prepared by either fast / slow evaporation crystallization in 2-Me-THF or fast evaporation of THF.

[0221] Free base Form IV is agglomerated small crystals with low crystallinity. XRPD results for free base Form IV are shown in Figure 7, and DSC and TGA results are shown in Figure 8. TGA shows a 36.9% weight loss before 210°C, attributed to desolvation. DSC reveals multiple endothermic peaks before 250°C. Form IV becomes amorphous upon heating to 170°C. Therefore, Form IV is a hydrate or solvate.

[0222] As can be seen from Figure 7, the X-ray powder diffraction peak data of the free base crystal form IV are shown in Table 8.

[0223] Table 8

[0224] 3.5 Free base form V

[0225] The free base crystal form V is obtained by slow volatilization in a MEK or DCM system, slurrying of DCM or cooling crystallization.

[0226] The sample obtained from the MEK system was characterized. The free base Form V is needle-shaped crystals with moderate crystallinity. The XRPD results of the free base Form V are shown in Figure 9, and the DSC and TGA results are shown in Figure 10. The TGA curve shows a 5.2% weight loss from 60 to 170°C, which is attributed to desolvation. The DSC shows multiple endothermic peaks before 250°C. After heating to 175°C, the free base Form V transforms into an amorphous form. Therefore, the free base Form V is a hydrate or solvate.

[0227] As can be seen from Figure 9, the X-ray powder diffraction peak data of the free base crystal form V are shown in Table 9.

[0228] Table 9

[0229] 3.6 Free base form VI

[0230] Free base Form VI was prepared from the slow volatilization of THF and characterized. Free base Form VI is agglomerated small crystals with moderate crystallinity. The DSC and TGA results are shown in Figure 12. TGA shows a 2.6% weight loss before 90°C and a 5.5% weight loss between 90°C and 195°C, which is attributed to the removal of solvent. Free base Form VI converts to an amorphous form upon heating to 195°C. DSC detected multiple endothermic peaks before 250°C, therefore, free base Form VI may be a solvate or a hydrate.

[0231] As can be seen from Figure 11, the X-ray powder diffraction peak data of the free base form VI are shown in Table 10.

[0232] Table 10

[0233] 3.7 Free base form VII

[0234] The free base crystal form VII is obtained by beating in a 2-Me-THF system at room temperature or at a high temperature of 50°C for 7 days. The free base crystal form VII is agglomerated small particle crystals with medium crystallinity. 1H-NMR detected that the sample contained 0.97% 2-Me-THF residual. The DSC and TGA results are shown in Figure 14. TGA showed a 1.7% weight loss between 85-240°C, which was attributed to the removal of the solvent. DSC detected two overlapping endothermic peaks at 230°C, which were attributed to the melting point. The crystal form of the free base crystal form VII did not change after being heated to 210°C. Therefore, the free base crystal form VII is an anhydrous crystal form.

[0235] As can be seen from Figure 13, the X-ray powder diffraction peak data of the free base form VII are shown in Table 11.

[0236] Table 11

[0237] 3.8 Free base form VIII

[0238] The free base form VIII was obtained by slurrying in water at 50°C for 7 days. The XRPD spectra of the wet and dry samples were not completely consistent, and the peaks of the free base form VIII shifted to a certain extent under different conditions. The DSC and TGA results are shown in Figure 16. After the sample was dried at 40°C, the TGA results showed that there was still more than 3.2% weight loss before 160°C. DSC showed multiple endothermic peaks before 250°C. 1H-NMR did not detect obvious residual solvent. When the compound was heated to 180°C, the crystalline form was converted into an amorphous form. Therefore, the free base form VIII may be a hydrate.

[0239] As shown in Figure 15, the X-ray powder diffraction peak data of the dried free base form VIII are shown in Table 12.

[0240] Table 12

[0241] 3.9 Free base form IX

[0242] Free base Form IX was obtained by precipitation from the antisolvent of DMSO / H₂O. Free base Form IX is a small crystalline particle with medium crystallinity. 1H-NMR analysis revealed 11.54% residual DMSO. DSC and TGA results are shown in Figure 18. TGA revealed a 2.1% weight loss before 85°C and an 11.5% weight loss from 85°C to 260°C, attributed to solvent removal. DSC revealed a broad endothermic peak at 37°C and another endothermic peak at 140°C. Therefore, free base Form IX is likely a DMSO solvate.

[0243] As can be seen from Figure 17, the X-ray powder diffraction peak data of the free base crystal form IX are shown in Table 13.

[0244] Table 13

[0245] 3.10 Free base amorphous

[0246] A free base Form I sample was weighed and dissolved in 20 mL of dichloromethane at room temperature. After filtration, the filtrate was quickly removed from the solvent by rotary evaporation. The resulting solid sample was subjected to corresponding characterization tests, and its XRD spectrum is shown in FIG44 .

[0247] 4 Conclusions of free base crystal form research:

[0248] Table 14

[0249] The compound represented by Formula (A) exhibited relatively complex polymorphic phenomena during polymorph screening, yielding nine crystalline forms, Forms I-IX. Two of these were anhydrous crystalline forms (Form III and Form VII), with Form III being relatively stable, possessing a higher melting point and enthalpy. The others were solvates or hydrates. Data are summarized in Table 14.

[0250] In the present invention, the 2θ angle values ​​of X-ray powder diffraction peaks have an error range of ±0.2°. It should be understood that the 2θ values ​​of X-ray powder diffraction patterns may vary slightly between machines and between samples, and their numerical range may differ within ±0.2 units. Therefore, the quoted values ​​are not to be interpreted as absolute values.

[0251] The free base crystal form III is an anhydrous crystalline form with a high melting point (245° C.). The free base crystal form III samples obtained by different solvents or methods are all small-particle crystals.

[0252] The free base crystal form III provided by the present invention has stable physical and chemical properties and is very suitable for application in subsequent drug development such as formulations.

[0253] The crystal forms I to IX provided by the present invention can be used to prepare RET inhibitor drugs, especially the crystal form III.

[0254] 3. Preparation and characterization of the acid salt of the compound represented by formula (A)

[0255] The 12 acids used in the salt screening of the present invention are shown in Table 15.

[0256] Table 15 Acid List

[0257] At room temperature, 30 mg of the free base (i.e., Form I free base prepared above) was added to various solvents, followed by the addition of an acid solution or solid acid (1.1 eq. or 0.6 eq.) to form a crystalline salt. If no solid precipitated, various crystallization methods were attempted to prepare the crystalline salt, such as cooling crystallization, evaporation crystallization, and antisolvent precipitation. The solid was collected by filtration, dried under vacuum, and further analyzed.

[0258] 1. Preparation and characterization of acid salt crystal form

[0259] 1.1 Hydrochloride Form I

[0260] At room temperature, approximately 30 mg of Form I free base was added to 1.0 mL of acetone. A hydrochloric acid solution (1.1 eq., 0.56 mol / L, concentrated hydrochloric acid dissolved in 0.1 mL of the corresponding solvent) was added to the suspension. Upon addition of the HCl solution, the suspension became a yellow, colloid-like substance. After 10 minutes, a solid precipitated. Stirring was continued for 2 days, and solid-liquid separation was performed to obtain Form I hydrochloride.

[0261] Hydrochloride Form I is agglomerated, fine crystals with moderate crystallinity. 1H-NMR analysis revealed no significant residual organic solvent. DSC and TGA results are shown in Figure 20. TGA analysis revealed a 1.7% weight loss before 150°C, attributable to the loss of water. DSC analysis revealed a broad endothermic peak during the initial heating phase, with two additional peaks detected at 173°C and 218°C. Therefore, Hydrochloride Form I is likely a hydrate.

[0262] Its powder X-ray diffraction pattern is shown in Figure 19, and the data are shown in Table 16:

[0263] Table 16

[0264] 1.2 p-Toluenesulfonate Crystalline Form I

[0265] At room temperature, approximately 30 mg of Form I free base was added to 1.0 ml of acetone. Upon addition of p-toluenesulfonic acid solution, the suspension became a nearly yellow, clear liquid. After 5 minutes, it became gelatinous. After 1 hour, solids precipitated. Stirring was continued for 2 days, and solid-liquid separation afforded Form I p-toluenesulfonate.

[0266] Form I of the p-toluenesulfonate salt exhibits agglomerated, fine crystals with high crystallinity. 1H-NMR analysis revealed 3.0% residual acetone, indicating a 1:1 molar ratio of acid to base. DSC and TGA results are shown in Figure 22. TGA results indicate a 3.0% weight loss before 210°C, attributed to the removal of acetone. DSC results reveal a broad endothermic peak at 163°C and another at 212°C. Therefore, Form I of the p-toluenesulfonate salt is likely a solvate.

[0267] Its powder X-ray diffraction pattern is shown in Figure 21, and the data are shown in Table 17:

[0268] Table 17

[0269] 1.3 Methanesulfonate Form I

[0270] At room temperature, approximately 30 mg of the free base Form I was added to 1.0 ml of acetone. Upon addition of methanesulfonic acid solution, the suspension became a yellow colloid. After 1 hour, solids precipitated. Stirring was continued for 2 days, followed by solid-liquid separation to obtain Form I, the methanesulfonate salt.

[0271] Methanesulfonate Form I is agglomerated, fine crystals with moderate crystallinity. 1H-NMR analysis revealed no significant residual organic solvent, and the acid-base molar ratio was 1:1. DSC and TGA results are shown in Figure 24. TGA results revealed a 0.4% weight loss before 100°C, attributed to water loss. DSC results revealed a small endothermic peak at 154°C and another at 192°C, attributed to sample melting. Therefore, Methanesulfonate Form I is likely an anhydrous form.

[0272] Its powder X-ray diffraction pattern is shown in Figure 23, and the data are shown in Table 18:

[0273] Table 18

[0274] 1.4 Benzenesulfonate Form I

[0275] At room temperature, approximately 30 mg of Form I free base was added to 1.0 mL of acetone. After the addition of benzenesulfonic acid solution, the suspension became a nearly yellow, clear liquid. After 30 seconds, a large amount of solid precipitated, and additional acetone (0.5 mL) was added. Stirring was continued for 2 days, and solid-liquid separation afforded Form I benzenesulfonate salt.

[0276] Form I of the benzenesulfonate salt is agglomerated, fine crystals with high crystallinity. 1H-NMR analysis revealed 0.19% residual acetone, indicating an acid-base molar ratio of 1:1. DSC and TGA results are shown in Figure 26. TGA results revealed no significant weight loss before 200°C. DSC results revealed an endothermic peak at 235°C, indicating melting of the compound. Therefore, Form I of the benzenesulfonate salt is an anhydrous form.

[0277] Its powder X-ray diffraction pattern is shown in Figure 25, and the data are shown in Table 19:

[0278] Table 19

[0279] 1.5 Oxalate Form I and Oxalate Form II

[0280] About 30 mg of free base Form I was added to methanol (1.0 ml) at room temperature. After the addition of oxalic acid solution, the suspension was stirred for 2 days, and the oxalate Form I was obtained by solid-liquid separation.

[0281] Oxalate Form I is a small, highly crystalline crystalline solid. 1H-NMR analysis revealed no significant residual methanol. DSC and TGA results are shown in Figure 28. TGA analysis revealed a 0.2% weight loss between 55°C and 85°C, attributed to water loss. DSC analysis revealed two small endothermic peaks at 43°C and 81°C, and another endothermic peak at 229°C, attributed to water loss and melting. Therefore, Oxalate Form I is likely an anhydrous form.

[0282] The powder X-ray diffraction pattern of the oxalate salt form I is shown in FIG27 , and the data are shown in Table 20:

[0283] Table 20

[0284] At room temperature, approximately 30 mg of Form I free base was added to acetone (1.0 mL). Upon addition of oxalic acid solution (1.1 eq., 0.56 mol / L, oxalic acid dissolved in 0.1 mL of the corresponding solvent), the suspension became a yellow colloid. After 2 minutes, a large amount of solid precipitated. Additional acetone (0.5 mL) was added, and stirring was continued for 2 days. Solid-liquid separation afforded Form II oxalate.

[0285] Oxalate Form II is agglomerated, fine crystals with high crystallinity. 1H-NMR analysis revealed 0.07% residual acetone. DSC and TGA results are shown in Figure 30. TGA analysis revealed no significant weight loss before 200°C. DSC analysis revealed an endothermic peak at 227°C, attributed to sample melting. Therefore, Oxalate Form II is an anhydrous form.

[0286] The powder X-ray diffraction pattern of the oxalate salt form II is shown in FIG29 , and the data are shown in Table 21 :

[0287] Table 21

[0288] 1.6 Maleate salt form I

[0289] At room temperature, approximately 30 mg of Form I free base was added to 2-methyltetrahydrofuran (1.0 mL). Maleic acid solution (1.1 eq., 0.56 mol / L, maleic acid dissolved in 0.1 mL of the corresponding solvent) was added, and the suspension was stirred for 2 days. Solid-liquid separation was performed to obtain Form I maleate salt.

[0290] Maleate salt Form I exhibits small, highly crystalline crystals. 1H-NMR analysis revealed a sample containing 0.41% residual 2-Me-THF, with an acid-base molar ratio of 1:1. DSC and TGA results are shown in Figure 32. TGA analysis revealed no significant weight loss before 150°C. DSC analysis revealed an endothermic peak at 175°C, representing the melting point of the compound. Therefore, Maleate Salt Form I is an anhydrous form.

[0291] The powder X-ray diffraction pattern of maleate salt form I is shown in FIG31 , and the data are shown in Table 22:

[0292] Table 22

[0293] 1.7 Phosphate Crystal Form I

[0294] At room temperature, approximately 30 mg of the free base Form I was added to the selected solvent. A phosphoric acid solution (1.1 eq., 0.56 mol / L, phosphoric acid dissolved in 0.1 mL of the corresponding solvent) was added to the suspension. The experimental process and results are shown in Table 23.

[0295] Table 23 Preparation of phosphate

[0296] Phosphate Form I is a fine crystal with high crystallinity. 1H-NMR analysis revealed approximately 0.06% residual acetone. DSC and TGA results are shown in Figure 34. TGA analysis revealed no significant weight loss before 200°C. DSC analysis revealed an endothermic peak at 221°C, which is attributed to the melting point of the compound. Therefore, Phosphate Form I is likely an anhydrous form.

[0297] The powder X-ray diffraction pattern of the phosphate crystal form I is shown in Figure 33, and the data are shown in Table 24:

[0298] Table 24

[0299] 1.8 Tartrate Form I

[0300] At room temperature, approximately 30 mg of Form I free base was added to the selected solvent. Solid tartaric acid (1.1 eq.) was added to the suspension. The experimental procedure and results are shown in Table 25.

[0301] Table 25 Preparation of tartrate

[0302] Tartrate Form I is agglomerated, fine crystals with moderate crystallinity. 1H-NMR analysis revealed approximately 0.08% residual acetone, indicating an acid-base molar ratio of 1:1. DSC and TGA results are shown in Figure 36. TGA analysis revealed a 1.7% weight loss before 105°C and a 0.6% weight loss between 105°C and 165°C. DSC revealed a broad endothermic peak at 40°C and two additional endothermic peaks at 146°C and 181°C, attributed to dehydration. Therefore, Tartrate Form I is likely a hydrate.

[0303] The powder X-ray diffraction pattern of the tartrate salt form I is shown in Figure 35, and the data are shown in Table 26:

[0304] Table 26

[0305] 1.9 Fumarate Form I

[0306] At room temperature, approximately 30 mg of free base Form I was added to 2-Me-THF, and solid fumaric acid (1.1 eq.) was added to the suspension. The experimental process and results are shown in Table 27.

[0307] Table 27 Preparation of fumarate

[0308] Fumarate Form I exhibits agglomerated, fine crystals with high crystallinity. 1H-NMR analysis indicates an acid-base molar ratio of 1:2. DSC and TGA results are shown in Figure 38. TGA results show no significant weight loss before 200°C. DSC reveals an endothermic peak at 239°C, which is attributed to the melting point of the compound. Therefore, Fumarate Form I is an anhydrous form.

[0309] The powder X-ray diffraction pattern of the fumarate salt form I is shown in Figure 37, and the data are shown in Table 28:

[0310] Table 28

[0311] 1.10 Citrate Form I

[0312] About 30 mg of free base Form I was added to acetone (1.0 ml) at room temperature. Solid citric acid (1.1 eq.) was added to the suspension and stirred for 2 days. Form I citrate was obtained by solid-liquid separation.

[0313] Form I citrate salt consists of agglomerated, fine crystals of medium crystallinity. 1H-NMR analysis revealed approximately 0.08% residual acetone, indicating an acid-base molar ratio of 1:2. DSC and TGA results are shown in Figure 40. TGA analysis revealed a 4.1% weight loss between 120°C and 230°C, attributable to water loss. DSC analysis revealed two broad endothermic peaks at 85°C and 155°C, and another at 230°C, attributed to dehydration and the melting point. Therefore, Form I citrate salt is likely a hydrate.

[0314] The powder X-ray diffraction pattern of the citrate salt form I is shown in Figure 39, and the data are shown in Table 29:

[0315] Table 29

[0316] 1.11 Malate Form I

[0317] At room temperature, approximately 30 mg of Form I free base was added to the selected solvent. Solid malic acid (1.1 eq.) was added to the suspension. The experimental procedures and results are shown in Table 30.

[0318] Table 30 Preparation of malate

[0319] Malate Form I exhibits highly crystalline, agglomerated, fine crystals. 1H-NMR analysis revealed 0.06% residual acetone, indicating an acid-base molar ratio of 1:2. DSC and TGA results are shown in Figure 42. TGA analysis revealed a 0.2% weight loss before 60°C, attributed to the removal of water and acetone. DSC analysis revealed an endothermic peak at 217°C, attributed to the melting point. Therefore, Malate Form I is an anhydrous crystalline form.

[0320] The powder X-ray diffraction pattern of malate Form I is shown in FIG41 , and the data are shown in Table 31:

[0321] Table 31

[0322] 2. Analysis Method

[0323] 2.1 Polarized light microscopy (PLM)

[0324] PLM analysis was performed using an ECLIPSE LV100POL (Nikon, JPN) polarizing microscope. A small amount of sample was spread onto a glass slide, cedar oil was added to disperse the sample, and a coverslip was applied. The sample was then observed under a microscope using a 4-20x objective lens.

[0325] 2.2 X-ray powder diffraction (XRPD)

[0326] Solid samples were tested using an X-ray diffractometer. The samples were spread flat on a zero-background single crystal silicon sample plate, gently pressed flat, and analyzed according to the parameters in Table 32.

[0327] Table 32 XRPD test parameters

[0328] 2.3 Thermogravimetric analysis (TGA)

[0329] TGA data for the samples were collected using a TA instrument. 1-5 mg of sample was placed in a tareed, open aluminum sample pan. The sample was heated according to the instrument parameters in Table 33, and the data was analyzed and processed using TRIOS software.

[0330] Table 33 TGA test parameters

[0331] 2.4 Differential Scanning Calorimetry (DSC)

[0332] DSC data for the samples were collected using a TA instrument. 1-3 mg of sample was placed in a perforated DSC pan and heated according to the parameters in Table 34. The data was analyzed and processed using TRIOS software.

[0333] Table 34 DSC test parameters

[0334] 2.5 Dynamic Vapor Sorption (DVS)

[0335] Moisture sorption and desorption analysis of samples was performed using a DVS instrument. A certain amount of sample was placed in a tared sample pan, and the sample weight was automatically measured. The sample was analyzed according to the parameters in Table 35.

[0336] Table 35 DVS analysis parameters of anhydrous crystal

[0337] 2.6 Nuclear Magnetic Resonance Mass Spectrometry ( 1 H-NMR)

[0338] 1H-NMR data were collected using a Bruker 400 MHz instrument. DMSO-d6 was used as the solvent, and the test parameters are shown in Table 36. Data were analyzed and processed using MestReNova software.

[0339] Table 36 1 H-NMR test parameters

[0340] 2.7 High Performance Liquid Chromatography (HPLC)

[0341] HPLC analysis was performed using an Agilent HPLC 1260 series instrument. The HPLC method for solubility and stability testing is shown in Table 37.

[0342] Table 37 HPLC method for solubility and stability testing

[0343] 3. Evaluation of the acid salt and free base crystal forms of the compound represented by formula (A)

[0344] In this salt screening study, eight anhydrous crystalline forms were obtained: methanesulfonate, benzenesulfonate, two oxalates, maleate, phosphate, fumarate and malate.

[0345] Based on the solid-state characterization data of the salt and the free-state crystal screening results, fumarate crystal form I, malate crystal form I and free base crystal form III were selected for solubility, stability and drug metabolism studies.

[0346] 3.1 Solubility study

[0347] The solubility of the fumarate salt form I and the malate salt form I was tested in biological media and water at 37° C. The results are shown in Table 38.

[0348] The maximum solubility of fumarate form I and malate form I occurred in SGF medium at 0.5 h (0.21 mg / mL and 0.20 mg / mL, respectively), and the solubility decreased with time. All crystalline forms were almost insoluble in water ( <LOQ)。

[0349] Table 38 Solubility test results

[0350] LOQ: ~1.0 μg / mL

[0351] The solubility of the salts was calculated using the free base.

[0352] 3.2 Solid-state stability study

[0353] The solid state stability of fumarate form I, malate form I and free base form III was tested at 60°C / closed and 40°C / 75% RH for 7 days. The experimental results are shown in Table 39.

[0354] As shown in Table 39, the fumarate salt Form I, malate salt Form I, and free base Form III exhibit good crystalline stability, with the crystalline forms of the three compounds remaining unchanged under both test conditions. While the chemical purity of the fumarate salt Form I decreased slightly at 40°C / 75% RH, it also exhibited good stability under closed-cup, high-temperature conditions. Humidity control was required during storage. The remaining two forms exhibited good chemical stability under both conditions.

[0355] Table 39 Stability evaluation results

[0356] 3.3 Evaluation of the free base amorphous form

[0357] 100 mg of the free base amorphous sample obtained in the present invention was weighed and solvent was added to form a suspension, and stirred at room temperature for 2 days. The results are as follows:

[0358] From the above results, it can be seen that the free base amorphous sample is unstable and can easily be converted into other crystalline forms in the solvent.

[0359] 3.4 Drug metabolism studies

[0360] Fumarate Form I, malate Form I, free base Form I and free base Form III were subjected to in vivo drug metabolism experiments in rats and dogs.

[0361] SD rats were given a single oral administration of fumarate form I, malate form I, free base form I and free base form III. Blood samples were collected at different time points to determine the drug concentrations in the rat plasma after administration of the test substances and calculate the relevant pharmacokinetic parameters.

[0362] Dogs were given a single oral dose of fumarate salt form I, free base form I, and free base form III. Blood samples were collected at different time points to determine the drug concentrations in dog plasma after administration of the test substances and calculate the relevant pharmacokinetic parameters.

[0363] 3.4.1 Preparation of test sample solution

[0364] The preparation method is as follows:

[0365] The solvent for Fumarate Form I, Malate Form I, Free Base Form I, and Free Base Form III is 0.5% MC + 1% Tween 80. The specific preparation method is as follows: Take 10 mg of the test sample, add 0.5% MC and 1% Tween 80, and vortex mix to obtain a 1 mg / mL solution. Prepare freshly before use, vortex mix thoroughly, and set aside.

[0366] 3.4.2. Analysis of test solution

[0367] The prepared test solution was tested and analyzed by the analytical department of this laboratory using LC-MS / MS.

[0368] 3.4.3 Animal reception and adaptation

[0369] Healthy male SD rats or dogs were used in this study. All animals were fasted before administration and resumed feeding 4 hours after administration.

[0370] 3.4.4 Sample collection and processing

[0371] Blood collection time points are:

[0372] Oral administration: 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours after administration. (±2 minutes for time points ≤2 hours, ±15 minutes for other time points.)

[0373] Approximately 0.1 mL of blood was collected from each animal via the jugular vein, using EDTA or sodium heparin as an anticoagulant. After collection, the blood samples were placed on ice and centrifuged to separate the plasma (centrifugation conditions: 10,000 rpm, 5 minutes, 4°C).

[0374] Plasma samples were analyzed by LC-MS / MS at the laboratory's analytical department.

[0375] 3.4.5 Pharmacokinetic Analysis

[0376] According to the blood concentration data of the drug, the pharmacokinetic parameters AUC of the test product were calculated using the pharmacokinetic calculation software WinNonlin non-compartmental model. 0→t , AUC 0→∞ 、C max 、T max and T1 / 2 and its mean and standard deviation.

[0377] 3.4.6 Experimental Results

[0378] The main pharmacokinetic parameters in plasma after a single oral administration of fumarate crystal form I, malate crystal form I, free base crystal form I and free base crystal form III are shown in Tables 40 and 41.

[0379] Table 40 Pharmacokinetic parameters in rats

[0380] Table 41 Pharmacokinetic parameters in dogs

[0381] The pharmacokinetic results above demonstrate that, in both rat and dog pharmacokinetic data, the in vivo exposure of fumarate Form I, malate Form I, and free base Form III is higher than that of free base Form I. PLM plots of free base Form I from two batches are shown in Figures 45 and 46 . As can be seen from the figures, all of the free base Form I particles are small agglomerates, making filtration very difficult during actual production and unfavorable for scale-up.

[0382] In summary, the fumarate form I and malate form I have excellent in vivo exposure in animals, good solid-state stability, and are suitable for scale-up production and further research and development.

[0383] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims

1. A crystalline form of a compound of formula A, characterized in that: The crystal form is selected from the following group: free base crystal form III, fumarate crystal form I, malate crystal form I, in, The X-ray powder diffraction pattern of the free base crystalline form III has characteristic peaks at the following 2θ values: 5.1±0.2°, 5.8±0.2°, 7.3±0.2°, 8.2±0.2°, 9.3±0.2°, 10.4±0.2°, 10.7±0.2°, 13.0±0.2°, 13.3±0.2°, 14.7±0.2°, 16.7±0.2°, 18.4±0.2°, 19.0±0.2°, 23.4±0.2°; The X-ray powder diffraction spectrum of the fumarate salt form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 8.7±0.2°, 10.6±0.2°, 14.6±0.2°, 15.5±0.2°, 17.5±0.2°, 18.0±0.2°, 19.2±0.2°, 27.1±0.2°; The X-ray powder diffraction pattern of the malate crystalline form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 9.3±0.2°, 10.7±0.2°, 11.2±0.2°, 11.8±0.2°, 15.3±0.2°, 17.3±0.2°, 17.6±0.2°, 18.3±0.2°, 19.0±0.2°, 23.5±0.2°, 25.7±0.2°, and 28.0±0.2°.

2. The crystal form according to claim 1, characterized in that: The X-ray powder diffraction pattern of the free base crystalline form III has characteristic peaks at the following 2θ values: 5.1±0.2°, 5.8±0.2°, 7.3±0.2°, 7.8±0.2°, 8.2±0.2°, 9.3±0.2°, 10.4±0.2°, 10.7±0.2°, 11.0±0.2°, 13.0±0.2°, 13.3±0.2°, 14.0±0.2°, 14.7±0.2°, 15.2±0.2°, 16.7±0.2°, 17.5±0.2°, 18.4±0.2°, 19.0±0.2°, 21.1±0.2°, 22.2±0.2°, 23.4±0.2°, 29.5±0.2°; The X-ray powder diffraction pattern of the fumarate salt form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 8.7±0.2°, 10.6±0.2°, 11.0±0.2°, 11.9±0.2°, 12.1±0.2°, 12.5±0.2°, 14.6±0.2°, 15.5±0.2°, 15.9±0.2°, 17.5±0.2°, 18.0±0.2°, 19.2±0.2°, 26.7±0.2°, 27.1±0.2°; The X-ray powder diffraction pattern of the malate crystalline form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 9.3±0.2°, 10.2±0.2°, 10.7±0.2°, 11.2±0.2°, 11.8±0.2°, 13.2±0.2°, 15.3±0.2°, 16.2±0.2°, 17.3±0.2°, 17.6±0.2°, 18.3±0.2°, 19.0±0.2°, 23.5±0.2°, 24.8±0.2°, 25.7±0.2°, 27.6±0.2°, and 28.0±0.2°.

3. The crystal form according to claim 1, characterized in that: The X-ray powder diffraction pattern of the free base crystalline form III has characteristic peaks at the following 2θ values: 5.1±0.2°, 5.8±0.2°, 7.3±0.2°, 7.8±0.2°, 8.2±0.2°, 9.3±0.2°, 10.4±0.2°, 10.7±0.2°, 11.0±0.2°, 13.0±0.2°, 13.3±0.2°, 14.0±0.2°, 14.7±0.2°, 15.2±0.2°. .2°, 16.7±0.2°, 17.5±0.2°, 18.4±0.2°, 19.0±0.2°, 21.1±0.2°, 21.6±0.2°, 22.2±0.2°, 23.4±0.2°, 24.9±0.2°, 25.9±0.2°, 26.3±0.2°, 27.9±0.2°, 28.4±0.2°, 29.5±0.2°, 30.0±0.2°, 35.6±0.2°; The X-ray powder diffraction spectrum of the fumarate salt form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 8.2±0.2°, 8.7±0.2°, 9.9±0.2°, 10.6±0.2°, 11.0±0.2°, 11.9±0.2°, 12.1±0.2°, 12.5±0.2°, 14.6±0.2°, 15.8±0.2°, 16.0±0.2°, 17.1±0.2°, 18.8±0.2°, 19.9±0.2°, 20.4±0.2°, 21.3±0.2°, 22.4±0.2°, 23.9±0.2°, 24.8±0.2°, 25.9±0.2°, 26.8±0.2°, 27.9±0.2°, 28. 5.5±0.2°, 15.9±0.2°, 16.5±0.2°, 17.5±0.2°, 18.0±0.2°, 19.2±0.2°, 21.2±0.2°, 22.2±0.2°, 23.9±0.2°, 25.5±0.2°, 26.7±0.2°, 27.1±0.2°, 28.8±0.2°; The X-ray powder diffraction spectrum of the malate crystalline form I has characteristic peaks at the following 2θ values: 6.0±0.2°, 9.3±0.2°, 10.2±0.2°, 10.7±0.2°, 11.2±0.2°, 11.8±0.2°, 12.1±0.2°, 13.2±0.2°, 15.3±0.2°, 16.2±0.2°, 16.8±0.2°, 17.1±0.2°, 17.3±0.2°, 17.6±0.2°, 18.3±0.2°, 19.0±0.2°, 23.5±0.2°, 24.8±0.2°, 25.2±0.2°, 25.7±0.2°, 27.6±0.2°, 28.0±0.2°, 29.7±0.2°.

4. The crystal form according to claim 1, characterized in that: The X-ray powder diffraction pattern of the free base Form III is substantially as shown in FIG5 ; The X-ray powder diffraction pattern of the fumarate salt form I is substantially as shown in FIG37 ; The X-ray powder diffraction pattern of the malate crystalline form I is basically shown in Figure 41.

5. The crystal form according to claim 1, characterized in that: The crystal form is selected from the following group: fumarate crystal form I and malate crystal form I.

6. The crystal form according to claim 1, characterized in that: The crystal form is fumarate crystal form I.

7. A method for preparing free base crystal form III, characterized in that: The method is selected from the group consisting of: Method 1: Mix the compound represented by formula A with solvent m, dissolve it, and crystallize it; the solvent m is selected from one of n-butyl ketone, acetone and acetonitrile; Method 2: Mix the compound represented by formula A with solvent n, beat at high temperature, and crystallize out; the solvent n is selected from one of ethyl acetate, isopropyl acetate and methyl tert-butyl ether.

8. A method for preparing fumarate crystalline form I or malate crystalline form I, characterized in that: The method is selected from the group consisting of: Method 1: dissolving the compound of formula A in an organic solvent, stirring at room temperature, then adding fumaric acid or malic acid, continuing stirring, and performing solid-liquid separation to obtain the fumarate salt crystal form I or malate salt crystal form I; Method 2: adding an organic solvent to the fumarate or malate of the compound of formula A, suspending and stirring, and performing solid-liquid separation to obtain the fumarate crystal form I or malate crystal form I.

9. A use of the crystal form according to claim 1, characterized in that: For use in the preparation of a medicament for use selected from the group consisting of: 1) Treating diseases or conditions associated with RET regulation; 2) Treat tumors; 3) Inhibit cell proliferation.

10. The use according to claim 9, characterized in that The tumor is selected from the group consisting of thyroid cancer and non-small cell lung cancer.

Citation Information

Patent Citations

  • Compound used as RET kinase inhibitor and application thereof

    CN113698390A

  • N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient

    WO2020175968A1

  • Compound used as RET kinase inhibitor and application thereof

    WO2020233641A1